AstraZeneca CEO Criticizes Refusal of Breast Cancer Treatment by Public Health Body The chief executive of AstraZeneca, Sir Pascal Soriot, has expressed disappointment over the decision of the National Institute for Health and Care Excellence (NICE) to deny access to the company’s breast cancer treatment, Enhertu, for NHS patients in England and Wales. According to NICE, the drug did not provide…
